Lupin is currently trading at Rs. 1429.00, up by 23.90 points or 1.70% from its previous closing of Rs. 1405.10 on the BSE.
The scrip opened at Rs. 1424.00 and has touched a high and low of Rs. 1430.00 and Rs. 1405.00 respectively. So far 26167 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1911.55 on 09-Feb-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs 1474.00 and Rs. 1399.00 respectively. The current market cap of the company is Rs. 64276.08 crore.
The promoters holding in the company stood at 46.74%, while Institutions and Non-Institutions held 41.85% and 11.41% respectively.
Pharma Major Lupin has received tentative approval for its Olmesartan Medoximil Tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Daiichi Sankyo Inc’s Benicar Tablets, 5 mg, 20 mg and 40 mg. The company’s Olmesartan Medoximil Tablets are the AB rated generic equivalents of Daiichi Sankyo Inc’s Benicar Tablets. Olmesartan Medoximil Tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents to lower blood pressure. Benicar Tablets had US sales of $1.06 billion (IMS MAT September 2016).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |